FlyteHealth

We’re a proud leader in tech-enabled medical care for people with obesity and comorbid health conditions. Today, we are rebranding as FlyteHealth for our customer and consumer-facing brand. “As our business in the care and navigation of the best-in-class obesity medicine program continues to grow, employers, payers and patients have come to know us as Flyte. With that increased visibility, we are consolidating under FlyteHealth as a single brand,” our CEO and co-founder Sloan Saunders explains. “This alignment allows us to continue to expand our offerings with our partners and provide a unified experience.” Powered by the patent-pending Flyte Intelligence platform, FlyteHealth delivers a user-friendly experience through the FlyteHealth app, care by a team of obesity medicine experts, and patient navigation services. The FlyteHealth approach is built upon the largest data set of obesity and chronic disease research available, as well as the decades of clinical experience of FlyteHealth’s founders — obesity medicine specialists who were among the first to see obesity not as a simple issue of willpower but as a complex disease that requires expert medical treatment. To learn more about our delivery of cost-effective care for obesity and related conditions, visit https://lnkd.in/gKdCZJwf.

Attend HLTH USA to learn more about our mission to transform care for people with obesity and chronic conditions.

Our co-founder, Katherine Saunders, MD, recently shared her insights with Healio on a new Senate bill targeting transparency in pharmaceutical advertising. Dr. Saunders emphasized the importance of requiring social media influencers to disclose payments from pharmaceutical companies, helping patients understand why a medication might be promoted. “Our patients are extremely vulnerable,” Dr. Saunders explained. “Most have tried countless treatments over the years, and many are searching for an effective, long-term solution.” At FlyteHealth, we are committed to empowering patients with transparent, evidence-based care. Read the full article: https://lnkd.in/gCCKWazy

The only true way to help individuals living with obesity is through clinical management while leveraging AI-based apps and connected devices to modify behavior over time (lifestyle management). That combined approach is what sets FlyteHealth apart. Read more: https://lnkd.in/gSex6dEp

FlyteHealth is proud to base our clinical model on the pioneering research of Dr. Louis Aronne. Our dedicated care team combines clinical management with behavioral modification tools to deliver superior outcomes for patients with obesity and chronic conditions. Join us at HLTH 2024 to explore how we can help your organization achieve these results!

Our clinical advisor, Dr. Caroline Apovian, also spoke with Healio about the serious issue of misinformation around obesity medications, and about how online influencers and companies framing GLP-1 anti-obesity medications as "weight loss drugs" undermine obesity treatment, which goes beyond just medication. Read more: https://lnkd.in/gCCKWazy

What sets FlyteHealth apart? It’s our comprehensive approach to managing obesity. From personalized treatment plans and connected devices to lifestyle modification, we provide optimal care through a dedicated care team. See how we’re blending clinical expertise with digital health at HLTH USA Oct. 20 -23! Save $150 with code FlyteHealth150: www.hlth.com/2024event

At FlyteHealth, the results speak for themselves. Over the past 12 months, our unique approach to obesity care has achieved: 💥 16.6% average weight loss 💥 14% reduction in blood pressure 💥 Costs for obesity medications, including GLP-1s, leveling off after years of increases Hear more about these outcomes at HLTH USA and why FlyteHealth is the future of healthcare. Learn more: https://lnkd.in/gSex6dEp

While many are jumping on the GLP-1 bandwagon, at FlyteHealth, we take a more strategic approach. We empower employers and payers to provide top-tier obesity care without skyrocketing costs. Our clinicians prescribe GLP-1 medications thoughtfully, alongside lower-cost generics, tailoring treatment to meet each patient’s unique needs. This approach delivers better outcomes for patients and more control over healthcare expenses. It's a win-win for both health and cost management.

Our co-founder and obesity medicine specialist, Katherine Saunders, MD, was featured in Healio discussing the recently introduced Protecting Patients from Deceptive Drug Ads Online Act. Dr. Saunders emphasized that high-quality obesity care goes beyond medications—it requires a multidisciplinary team offering evidence-based, patient-centered treatment. Learn more: https://lnkd.in/gCCKWazy